AMGNAmgenRunning, no new patients
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Small-cell Lung Cancer · Extensive Stage Small-cell Lung Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 350 (final count)
- Started
- Aug 18, 2025
- Main results expected
- Jan 4, 2029
- Fully finished
- Aug 15, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: Up to approximately 3.5 years
Progression free survival (PFS) (Blinded Independent Central Review [BICR] Assessed)
Measured over: Up to approximately 3.5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07005128 · record last updated 2026-09-08 · checked 2026-11-09 15:42 UTC